NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)
Edurant is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in people at least 18 years old who have HIV-1 RNA less than or equal to 100,000 copies/milliliter at the start of therapy. Edurant is approved for use in those who are just beginning antiretroviral treatment. Edurant is recommended in combination with other antiretroviral medications. Edurant is also referred to by its drug name, Rilpivirine, and by the abbreviation RPV. Rilpivirine is a component of the combination drug Complera.
Edurant is an antiviral medication of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Edurant is believed to work by preventing HIV from replicating in cells.
How do I take it?
Prescribing information states that Edurant is taken once or twice a day.
Edurant comes in tablet form.
The FDA-approved label for Edurant lists common side effects including vomiting, nausea, diarrhea, fatigue, depression, dizziness, headache, stomach pain, insomnia, unusual dreams, and changes in the shape or location of body fat.
Rare but serious side effects listed for Edurant include suicidal thoughts and severe chest pain.
For more details about this treatment, visit:
Edurant – RxList
Overview of HIV Treatments – AIDS.gov